Guidance on nitrosamine impurities in medications.: H164-327/2023E-PDF
"Evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products"--Cover.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.921323&sl=0
| Department/Agency | Canada. Health Canada, issuing body. |
|---|---|
| Title | Guidance on nitrosamine impurities in medications. |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Later edition | Guidance on nitrosamine impurities in medications. July 24, 2023 |
| Earlier edition | Guidance on nitrosamine impurities in medications. September 1, 2022 |
| Format | Electronic |
| Electronic document | |
| Note(s) | Cover title. "Date adopted: April 17, 2023. Effective date: April 17, 2023." Issued also in French under title: Lignes directrices sur les impuretés de nitrosamine dans les médicaments. Includes bibliographical references. |
| Publishing information | Ottawa, ON : Health Canada = Santé Canada, 2023. ©2023 |
| Description | 1 online resource (iii, 25 pages) |
| ISBN | 9780660482057 |
| Catalogue number |
|
| Departmental catalogue number | 230024 |
| Subject terms | Nitrosoamines -- Risk assessment -- Canada. Drugs -- Risk assessment -- Canada. Biologicals -- Risk assessment -- Canada. Radiopharmaceuticals -- Risk assessment -- Canada. Pharmaceutical policy -- Canada. |